Health Condition 1: F209- Schizophrenia, unspecified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Adult (>=18 years) patients of both gender attending the OPD of Psychiatry, AIIMS, Kalyani, diagnosed with schizophrenia (DSM V), and are adjudicated by the treating psychiatrist to be treated with one or more of the following first-line antipsychotic medicine: olanzapine, risperidone, haloperidol, amisulpride, quetiapine, aripiprazole, and trifluoperazine
Exclusion criteria
Exclusion criteria: Patients who are needed to be hospitalized or provided electroconvulsive therapy (ECT) at presentation, patients for whom any other antipsychotic drug is required to be initiated, and those who are unwilling to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in the Udvalg for Kliniske Undersøgelser Side-Effect Rating Scale (UKU-SERS) score between the two groupsTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients developing solicited AEs & SAEs The proportion of patients requiring hospitalization Duration of hospitalization Clinical response at week 12 (PANSS & CGI) Time-to-achieve clinical response through 12 weeks (PANSS & CGI) The proportion of patients non-responsive to treatment Number & olanzapine-equivalent doses of various anti-psychotics Medication adherence Quality of life (EQ-5D-5L) Correlation between serum drug level, dosing, & clinical response Health outcomes in terms of life years, QALYs, & costs Facilitators & challenges in implementing PGx-assisted treatmentTimepoint: 12 weeks | — |
Countries
India
Contacts
Indian Council of Medical Research - Centre for Ageing and Mental Health